Increased antibody response after SARS-CoV-2 mRNA-based vaccination in rituximab-treated patients with previous COVID-19 infection.
作者信息
Avouac Jérôme, Ghossan Roba, Al Tabaa Omar, Combier Alice, Steelandt Alexia, Thomas Marion, Fogel Olivier, Mariaggi Alice Andrée, Meritet Jean-François, Rozenberg Flore, Molto Anna, Miceli-Richard Corinne, Allanore Yannick
机构信息
Service de Rhumatologie.
Service de Virologie, Hôpital Cochin, AP-HP.CUP, Université de Paris, Paris, France.
出版信息
Rheumatology (Oxford). 2022 Jun 28;61(SI2):SI191-SI193. doi: 10.1093/rheumatology/keac201.
Abstract
摘要
相似文献
1
Increased antibody response after SARS-CoV-2 mRNA-based vaccination in rituximab-treated patients with previous COVID-19 infection.
Rheumatology (Oxford). 2022 Jun 28;61(SI2):SI191-SI193. doi: 10.1093/rheumatology/keac201.
2
Time Since Rituximab Treatment Is Essential for Developing a Humoral Response to COVID-19 mRNA Vaccines in Patients With Rheumatic Diseases.利妥昔单抗治疗后时间对于风湿性疾病患者对 COVID-19 mRNA 疫苗产生体液免疫反应至关重要。
J Rheumatol. 2022 Jun;49(6):644-649. doi: 10.3899/jrheum.211152. Epub 2022 Mar 1.
3
Antibody response to mRNA SARS-CoV-2 vaccination in 182 patients after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后 182 例患者对 mRNA SARS-CoV-2 疫苗的抗体反应。
Transpl Infect Dis. 2022 Jun;24(3):e13828. doi: 10.1111/tid.13828. Epub 2022 Apr 18.
4
Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients.利妥昔单抗治疗患者对 COVID-19 疫苗接种产生体液免疫应答受损的风险因素。
Rheumatology (Oxford). 2022 Jun 28;61(SI2):SI163-SI168. doi: 10.1093/rheumatology/keab815.
5
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.利妥昔单抗治疗患者的新型冠状病毒2型疫苗接种：体液免疫受损但细胞免疫反应可诱导的证据
Ann Rheum Dis. 2021 Oct;80(10):1355-1356. doi: 10.1136/annrheumdis-2021-220408. Epub 2021 May 6.
6
Low levels of anti-SARS-CoV-2 antibodies after vaccination in rituximab-treated patients: comment on the article by Simon et al.
Arthritis Rheumatol. 2022 May;74(5):908-909. doi: 10.1002/art.42011. Epub 2022 Apr 5.
7
Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.关于“利妥昔单抗治疗患者的新型冠状病毒2疫苗接种：体液免疫受损但细胞免疫可诱导的证据”的通信
Ann Rheum Dis. 2021 Oct;80(10):e162. doi: 10.1136/annrheumdis-2021-220756. Epub 2021 Jul 16.
8
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.抗肿瘤治疗的癌症患者接种 BNT162b2 冠状病毒病 2019 信使 RNA 疫苗后体液免疫应答降低。
ESMO Open. 2021 Oct;6(5):100274. doi: 10.1016/j.esmoop.2021.100274. Epub 2021 Sep 8.
9
SARS-CoV-2 anti-spike antibodies after vaccination in pediatric heart transplantation: A first report.接种疫苗后儿科心脏移植患者体内的 SARS-CoV-2 刺突抗体：首报。
J Heart Lung Transplant. 2022 Feb;41(2):133-136. doi: 10.1016/j.healun.2021.11.001. Epub 2021 Nov 14.
10
Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab.一名患有套细胞淋巴瘤并接受利妥昔单抗治疗的男性，在没有抗 SARS-CoV-2 抗体反应证据的情况下从严重持续性 COVID-19 中康复。
J Infect Chemother. 2022 Feb;28(2):329-332. doi: 10.1016/j.jiac.2021.11.018. Epub 2021 Nov 25.
本文引用的文献
1
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study.利妥昔单抗治疗的类风湿关节炎患者对两剂和三剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的体液和细胞免疫反应：一项前瞻性队列研究
Lancet Rheumatol. 2022 Mar;4(3):e177-e187. doi: 10.1016/S2665-9913(21)00394-5. Epub 2021 Dec 23.
2
Risk factors of impaired humoral response to COVID-19 vaccination in rituximab-treated patients.利妥昔单抗治疗患者对 COVID-19 疫苗接种产生体液免疫应答受损的风险因素。
Rheumatology (Oxford). 2022 Jun 28;61(SI2):SI163-SI168. doi: 10.1093/rheumatology/keab815.
3
Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19.有新冠病毒疾病既往史的肾移植受者在接种第一剂基于信使核糖核酸的新冠病毒疫苗后产生强烈抗体反应。
Am J Transplant. 2021 Nov;21(11):3808-3810. doi: 10.1111/ajt.16764. Epub 2021 Jul 23.
4
Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination.mRNA 疫苗接种后 SARS-CoV-2 初免者和康复者的抗体和记忆 B 细胞反应存在差异。
Sci Immunol. 2021 Apr 15;6(58). doi: 10.1126/sciimmunol.abi6950.
5
Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.既往感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）对单剂量BNT162b2疫苗体液和T细胞反应的影响
Lancet. 2021 Mar 27;397(10280):1178-1181. doi: 10.1016/S0140-6736(21)00502-X. Epub 2021 Feb 25.
6
Good and bad memories following rituximab therapy.利妥昔单抗治疗后的美好与糟糕回忆。
Arthritis Rheum. 2010 Jan;62(1):1-5. doi: 10.1002/art.25039.
Zotero 插件